ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CYCC Cyclacel Pharmaceuticals Inc

2.18
0.22 (11.22%)
After Hours
Last Updated: 19:30:22
Delayed by 15 minutes

Period:

Draw Mode:

Volume 46,138
Bid Price 2.04
Ask Price 2.19
News -
Day High 2.14

Low
1.8201

52 Week Range

High
13.20

Day Low 1.99
Company Name Stock Ticker Symbol Market Type
Cyclacel Pharmaceuticals Inc CYCC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.22 11.22% 2.18 19:30:22
Open Price Low Price High Price Close Price Prev Close
1.99 1.99 2.14 2.1099 1.96
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
294 46,138 $ 2.06 $ 95,116 - 1.8201 - 13.20
Last Trade Time Type Quantity Stock Price Currency
19:30:21 44 $ 2.10 USD

Cyclacel Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.78M 842.86k - 0 -21.4M -25.39 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cyclacel Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CYCC Message Board. Create One! See More Posts on CYCC Message Board See More Message Board Posts

Historical CYCC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.282.29791.82012.0447,626-0.10-4.39%
1 Month2.653.021.82012.4040,043-0.47-17.74%
3 Months2.383.651.82012.89161,157-0.20-8.40%
6 Months5.1011.3431.82014.56182,105-2.92-57.25%
1 Year8.8513.201.82015.66129,837-6.67-75.37%
3 Years110.85119.251.820128.05208,456-108.67-98.03%
5 Years261.60324.001.820188.84291,696-259.42-99.17%

Cyclacel Pharmaceuticals Description

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.

Your Recent History

Delayed Upgrade Clock